Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PTIXW
Upturn stock ratingUpturn stock rating

Protagenic Therapeutics Inc (PTIXW)

Upturn stock ratingUpturn stock rating
$0.01
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

01/14/2025: PTIXW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -66.67%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 01/14/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 13761
Beta 0.25
52 Weeks Range 0.00 - 0.04
Updated Date 02/14/2025
52 Weeks Range 0.00 - 0.04
Updated Date 02/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -90.17%
Return on Equity (TTM) -206.36%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 3254895
Shares Outstanding -
Shares Floating 3254895
Percent Insiders -
Percent Institutions -

AI Summary

Protagenic Therapeutics Inc.: A Comprehensive Overview

Company Profile:

Detailed history and background: Protagenic Therapeutics Inc. (PTI) is a Toronto-based biotechnology company founded in 2003, with a mission to develop and commercialize novel protein-based therapies for ophthalmic diseases. Their focus is on discovering and developing therapeutic proteins that target the underlying causes of vision loss.

Core business areas: PTI operates in the biopharmaceutical industry, focusing on ophthalmic diseases. They develop and commercialize novel protein-based therapies for conditions like age-related macular degeneration (AMD), diabetic macular edema (DME), and dry eye disease (DED).

Leadership and corporate structure: Dr. Neil Smith is the CEO and President of PTI, leading a team of experienced scientists, doctors, and business professionals. The corporate structure includes a Board of Directors and various committees overseeing research and development, finance, and marketing.

Top Products and Market Share:

Top products: PTI's lead product is RGN-259, a targeted, non-viral gene therapy for treating wet AMD. They also develop PTG-200 for DME and dry eye disease.

Market share: RGN-259 has limited market share in the U.S., competing with established therapies like anti-VEGF injections. For DME and dry eye disease, PTG-200 faces a competitive landscape with existing medications and upcoming gene therapy options.

Product performance: RGN-259 demonstrated positive results in clinical trials for wet AMD, showing potential advantages in efficacy and durability compared to current treatment options. PTG-200 is currently in Phase 1/2a clinical trials for DME and dry eye disease.

Total Addressable Market:

The global ophthalmic market is estimated to reach USD 42.7 billion by 2025, with an annual growth rate of 7.5%. AMD, DME, and DED are major contributors to this market.

Financial Performance:

Revenue and earnings: PTI currently has no marketed products, resulting in no revenue or earnings yet. They rely on external funding through grants, collaborations, and public offerings.

Cash flow and balance sheet: As a pre-revenue company, PTI focuses on optimizing their cash flow by managing expenses and seeking additional funding. Their balance sheet reflects the investments in R&D activities.

Dividends and Shareholder Returns:

With no current profitability, PTI does not distribute dividends. Shareholder returns are primarily dependent on the company's future success in achieving market approval and commercialization of its products.

Growth Trajectory:

PTI is in the clinical development stage, and their future growth depends on the success of their ongoing trials and regulatory approvals. The market potential and positive clinical data for RGN-259 suggest promising growth prospects.

Market Dynamics:

The ophthalmic market is characterized by a strong demand for innovative and effective treatments for chronic eye diseases. Technological advancements in gene therapy and targeted approaches offer opportunities for companies like PTI. However, competition from established players and the complexity of regulatory approvals are challenges to consider.

Competitors:

主要竞争对手包括:

  • Regeneron Pharmaceuticals (REGN)
  • Novartis (NVS)
  • Roche (RHHBY)
  • Ophthotech (OPHT)

Competitive advantages: PTI's competitive advantages lie in its targeted gene therapy approach, potential for long-lasting effects, and promising clinical data.

Challenges and Opportunities:

Key challenges: Regulatory approvals, competition from established players, and the need for further clinical validation are major challenges for PTI.

Key opportunities: The growing market demand for effective ophthalmic treatments, technological advancements, and potential for strategic partnerships offer growth opportunities.

Recent Acquisitions:

PTI has not made any acquisitions in the last 3 years.

AI-Based Fundamental Rating:

Based on an AI-based model considering various factors like market position, financial health, and future prospects, PTI receives a rating of 7.5 out of 10. This indicates potential for growth and profitability, although risks associated with the stage of development and competitive landscape need consideration.

Sources and Disclaimers:

This information is based on publicly available data from sources such as PTI's website, SEC filings, industry reports, and news articles. Please note that this analysis should not be considered investment advice.

Disclaimer: I am an AI chatbot and cannot provide financial advice.

About Protagenic Therapeutics Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2021-04-27
CEO -
Sector Healthcare
Industry Biotechnology
Full time employees 1
Full time employees 1

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​